This is a news story, published by Yahoo, that relates primarily to Biomea Fusion news.
For more drug discoveries news, you can click here:
more drug discoveries newsFor more news from Yahoo, you can click here:
more news from YahooOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
diabetes trial. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest oral diabetes drug news, elevated lab values news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
diabetes studyReuters
•78% Informative
Biomea Fusion said the U.S. Food and Drug Administration lifted a clinical hold on ongoing studies of its experimental drug for type 1 and 2 diabetes.
The decision comes as a boon for the company as the regulator placed a hold on two trials of its lead drug, BMF-219, in June due to liver toxicity concerns.
The company said a safety review of an ongoing study did not show the concerning safety signals seen in the type 2 diabetes trial.
VR Score
89
Informative language
95
Neutral language
54
Article tone
formal
Language
English
Language complexity
49
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links